Difference between revisions of "Peginterferon alfa-2a (Pegasys)"
m |
m |
||
Line 17: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*10/16/2002: Initial FDA approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa. | *10/16/2002: Initial FDA approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa. | ||
+ | |||
+ | ==Also known as== | ||
+ | *'''Brand name:''' Pegasys | ||
==References== | ==References== | ||
Line 22: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
+ | [[Category:Subcutaneous medications]] | ||
+ | [[Category:Pegylated medications]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
[[Category:Cytokines]] | [[Category:Cytokines]] |
Revision as of 03:48, 17 November 2017
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to Interferon alfa-2a (Roferon-A).[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 10/16/2002: Initial FDA approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa.
Also known as
- Brand name: Pegasys